Considering unmet medical needs and our technology platform, Auson focuses on improving the existing products to optimize dosing regimens, develop new dosage forms and new indications. These products will be filed using 505(b)(2) regulatory pathway in U.S. and class 2 of drugs registration classification pathway in China.